|
 |
J Clin Outcomes Manage
2008 Jan;15(1):31-38
Biologic agents in the treatment of Crohn's disease
Wilson J, Brown SJ
Abstract Objective: To review the role of the biologic agents in therapy for Crohn’s disease, with particular emphasis on efficacy, indications for use, and impact on disease outcomes. Methods: Qualitative review of the literature and expert opinion. Results: A number of biologic agents are showing great promise as therapeutics for Crohn’s disease. The best established are the anti–tumor necrosis factor-a compounds, of which infliximab is the prototype. Traditionally, these agents have been reserved for patients who have not responded adequately to “conventional” therapy, although there is increased interest in using these potent medications early, with a view to altering the natural history and the outcomes of this disease. Challenges remain, including identifying patients who are most likely to benefit from such agents and minimizing potential toxicity. Conclusion: Biologic agents will continue to expand the therapeutic options in Crohn’s disease and lead to improved patient outcomes.
Clinical Review
Search the Turner White index to find abstracts of articles published in JCOM.
|
